相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product-Induced Protein Arginine Methyltranferase-1 Expression
Ayako Ojima et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
M. Ferwana et al.
DIABETIC MEDICINE (2013)
Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF
Nobuhiro Tahara et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level
Yuji Ishibashi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes
Dana E. King et al.
PRIMARY CARE DIABETES (2012)
Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials
Adrian V. Hernandez et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2011)
Soluble Receptor of Advanced Glycated Endproducts Is Associated With Plaque Vulnerability in Patients With Acute Myocardial Infarction
Hun-Jun Park et al.
CIRCULATION JOURNAL (2011)
Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus
Ligia Petrica et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes
M. C. Thomas et al.
DIABETOLOGIA (2011)
Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis
Sayaka Maeda et al.
PHARMACOLOGICAL RESEARCH (2011)
Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe?
Sho-ichi Yamagishi et al.
PHARMACOLOGICAL RESEARCH (2011)
Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation
Takanori Matsui et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients
Ozen Oz Gul et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
N. Papanas et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients
Tsukasa Nakamura et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease
Sho-ichi Yamagishi et al.
PHARMACOLOGICAL RESEARCH (2009)
Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Sho-ichi Yamagishi et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system -: Role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor γ signaling during endothelial aging
Fortunato Scalera et al.
HYPERTENSION (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction
Friedrich Mittermayer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction - Results from the PROactive (PROactive 05) study
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome
Nobuhiro Tahara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells
Shan Wang et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes
Kazuo Nakamura et al.
MOLECULAR MEDICINE (2007)
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Aaron S. Kelly et al.
VASCULAR MEDICINE (2007)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
T. Yoshida et al.
DIABETOLOGIA (2006)
Relation of improvement in endothelium-dependent flow-mediated vasodilation after Rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome
Tzung-Dau Wang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Peroxisome proliferator-activated receptor γ down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model
K Wang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Association study between fibronectin and coronary heart disease
Y Zhang et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2006)
Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats
S Wakino et al.
HYPERTENSION RESEARCH (2005)
Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes
L Tarnow et al.
DIABETES CARE (2004)
AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type I receptor interaction
K Fukami et al.
KIDNEY INTERNATIONAL (2004)
Thiazolidinediones reduces endothelial expression of receptors for advanced glycation end products
N Marx et al.
DIABETES (2004)
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor
MC Stühlinger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
Y Miyazaki et al.
DIABETES CARE (2001)
分享论文
